Update of the vascular model of AMD

British Journal of Ophthalmology

Volumn 88, Issue 2, 2004, Pages 161-163

  Friedman, E ^a  

^a MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LIPID; STATIN; VASCULOTROPIN ANTIBODY;

CLINICAL TRIAL; DISEASE COURSE; EDITORIAL; EPIDEMIOLOGY; HUMAN; HYPERTENSION; MEDICAL RECORD; PRESCRIPTION; PRIORITY JOURNAL; RETINA MACULA DEGENERATION; RETROSPECTIVE STUDY; RISK FACTOR; SIDE EFFECT; STATISTICAL SIGNIFICANCE;

ANTIHYPERTENSIVE AGENTS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MACULAR DEGENERATION; MODELS, CARDIOVASCULAR; VASCULAR DISEASES;

EID: 0942279521     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2003.036277     Document Type: Editorial

References (29)

1. Friedman E. The role of the atherosclerotic process in the pathogenesis of age-related macular degeneration. Am J Ophthalmol 2000;130:658-63.
2. Friedman E. A hemodynamic model of the pathogenesis of age-related macular degeneration. Am J Ophthalmol 1997;124:677-82.
3. Friedman E, Smith T, Kuwabara T. Senile choroidal vascular patterns and drusen. Arch Ophthalmol 1963;69:220-30.
4. Malek G, Li CM, Guidry C, et al. Apolipoprotein B in cholesterol- containing drusen and basal deposits of human eyes with age-related maculopathy. Am J Pathol 2003;162:413-25.
5. Friedman E, Ivry M, Ebert E, et al. Increased scleral rigidity and age-related macular degeneration. Ophthalmology 1989;96:104-8.
6. Friedman E, Krupsky S, Lane A, et al. Ocular blood flow velocity in age-related macular degeneration. Ophthalmology 1995;102:640-6.
7. Broekhuyse RN. The lipid composition of aging sclera and cornea. Ophthalmologica 1975;171:82-5.
8. Bird A, Marshall J. Retinal pigment epithelial detachments in the elderly. Trans Ophthalmol Soc UK 1986;105:674-82.
9. Ikram MK, van Leeuwen R, Vingerling JR, et al. Reltionship between refraction and prevalent as well as incident age-related maculopathy: the Rotterdam Study. Invest Ophthalmol Vis Sci 2003;44:3778-82.
10. Del Priore LV, Kaplan H, Hornbeck R, et al. Retinal pigment epithelial debridment as a model for the pathogenesis and management of age related macular degeneration. Am J Ophthalmol 1996;122:629-43.
11. Dimitrova G, Tamaki Y, Kato S. Retrobulbar circulation in patients with age-related maculopathy. Eye 2002;16:580-6.
12. Ciulla TA, Harris A, Kagemann L. Choroidal perfusion perturbations in non-neovascular age related macular degeneration. Br J Ophthalmol 2002;86:209-13.
13. Grunwald JE, Hariprasad SM, DuPont J. Foveolar choroidal blood flow in age-related macular degeneration. Invest Ophthalmol Vis Sci 1998;38:385-91.
14. Friedman E. Central serous choroidopathy: pathogenesis and treatment. In: Brockhurst RI, Boruchoff SA, Hutchinson BT, Lessell S, eds. Controversy in ophthalmology. Philadelphia: Sounders, 1977:706-9.
15. Bischoff P, Flower R. High blood pressure in choroidal arteries as a possible pathogenetic mechanism in senile macular degeneration [letter]. Am J Ophthalmol 1983;96:388-99.
16. Hyman L, Schachat AP, He Q, et al. Hypertension, cardiovascular diseases, and age-related macular degeneration. Arch Ophthalmol 2000;117:351-8.
17. Van Leeuwen R, Ikram MK, Vingerling JR, et al. Blood pressure, atherosclerosis, and the incidence of age-related maculopothy: the Rotterdam Study. Invest Ophthalmol Vis Sci 2003;44:3771-7.
18. Moore MA. Drugs that interrupt the rennin-angiotensin system should be among the preferred initial drugs to treat hypertension. J Clin Hypert 2003;5:137-44.
19. Sjolie AK, Chaturvedi N. The retinal rennin-angiotensin system: implications for therapy in diabetic retinopathy. J Hum Hypertens 2002;(Suppl 3):S42-6.
20. Wilson AS, Hobbs BG, Shen WY, et al. Argon laser photocoagulation- induced modification of gene expression in the retina. Invest Ophthalmol Vis Sci 2003;44:1426-34.
21. Hamdi HK, Reznik J, Castellon K, et al. Alu DNA polymorphism in ACE gene is protective for age-related macular degeneration. Biochem Biophys Res Commun 2002;295:668-72.
22. Veillard NR, Mach F. Statins: the new aspirin? CMLS, Cell Mol Life Sci 2002;59:171-6.
23. Hall NF, Gale CR, Syddall H, et al. Risk of macular degeneration in users of statins: cross sectional study. BMJ 2001;323:375-6.
24. McCarty CA, Mukesh BN, Guymer RH, et al. Cholesterol-lowering medications reduce the risk of age-related maculopathy progression. Med J Aust 2001;175:340.
25. Wilson H, Bhatt HRF, Schwartz DM, et al. Statin therapy is associated with decreased odds of developing noevascular age-related macular degeneration. Invest Ophthalmol Vis Sci (Suppl) 2003:1804.
26. Chavis PS, Castillo IG, Schwartz SG, et al. Risk factors for age-related macular degeneration. Invest Ophthalmol Vis Sc (Suppl) 2003:5038.
27. Van Leeuwen R, Vingerling JR, Hofman A, et al. Cholesterol lowering drugs and risk of age-related maculopathy: prospective cohort study with cumulative exposure measurement. BMJ 2003;326:255-6.
28. Klein R, Klein B, Tomany SC, et al. Relation of statin use to the 5-year incidence and progression of age-related maculopathy. Arch Ophthalmol 2003;121:1151-5.
29. McGwin Jr G, Owsley, Curcio CA, et al. The association between statin use and age-related maculopathy. Br J Ophthalmol 2003;87:1121-5.